Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen.

Publication ,  Journal Article
Bennett-Guerrero, E; Sorohan, JG; Howell, ST; Ayuso, L; Cardigan, RA; Newman, MF; Mackie, IJ; Reves, JG; Mythen, MG
Published in: Anesth Analg
December 1996

Aprotinin concentrations in the range of 127-191 kallikrein inactivator units (KIU)/mL at the end of cardiopulmonary bypass (CPB) (< 2 h duration) reduce transfusion requirements. It has been suggested that prolonged CPB may require higher infusion rates which significantly increase cost. We tested the hypothesis that large-dose aprotinin maintains therapeutic plasma levels during prolonged periods of CPB (< 2 h). Aprotinin was administered as follows: 2 x 10(6) KIU upon skin incision; 0.5 x 10(6) KIU/h x 4-h infusion on initiation of CPB; and 2 x 10(6) KIU added to the CPB prime solution. Aprotinin activity was measured 1) 30 min after initiation of drug administration (Pre-CPB); 2) 30 min after initiation of CPB (CPB + 30); 3) 90 min after initiation of CPB (CPB + 90); and 4) at CPB termination (End CPB). CPB duration (mean +/- SD) was 158 +/- 51 min. Plasma aprotinin concentrations (KIU/mL, mean +/- SD) were: 234 +/- 30 at Pre-CPB; 229 +/- 35 at CPB + 30; 184 +/- 27 at CPB + 90; and 179 +/- 22 at End CPB. In all patients, aprotinin levels at the completion of CPB were in the range previously reported to be effective. The authors conclude that large-dose regimen limited to 6 x 10(6) KIU maintained therapeutic plasma aprotinin concentrations during prolonged CPB.

Duke Scholars

Published In

Anesth Analg

DOI

ISSN

0003-2999

Publication Date

December 1996

Volume

83

Issue

6

Start / End Page

1189 / 1192

Location

United States

Related Subject Headings

  • Time Factors
  • Middle Aged
  • Male
  • Internal Mammary-Coronary Artery Anastomosis
  • Infusions, Intravenous
  • Humans
  • Hemostatics
  • Hemofiltration
  • Heart Valves
  • Heart Arrest, Induced
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bennett-Guerrero, E., Sorohan, J. G., Howell, S. T., Ayuso, L., Cardigan, R. A., Newman, M. F., … Mythen, M. G. (1996). Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Anesth Analg, 83(6), 1189–1192. https://doi.org/10.1097/00000539-199612000-00010
Bennett-Guerrero, E., J. G. Sorohan, S. T. Howell, L. Ayuso, R. A. Cardigan, M. F. Newman, I. J. Mackie, J. G. Reves, and M. G. Mythen. “Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen.Anesth Analg 83, no. 6 (December 1996): 1189–92. https://doi.org/10.1097/00000539-199612000-00010.
Bennett-Guerrero E, Sorohan JG, Howell ST, Ayuso L, Cardigan RA, Newman MF, et al. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Anesth Analg. 1996 Dec;83(6):1189–92.
Bennett-Guerrero, E., et al. “Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen.Anesth Analg, vol. 83, no. 6, Dec. 1996, pp. 1189–92. Pubmed, doi:10.1097/00000539-199612000-00010.
Bennett-Guerrero E, Sorohan JG, Howell ST, Ayuso L, Cardigan RA, Newman MF, Mackie IJ, Reves JG, Mythen MG. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Anesth Analg. 1996 Dec;83(6):1189–1192.

Published In

Anesth Analg

DOI

ISSN

0003-2999

Publication Date

December 1996

Volume

83

Issue

6

Start / End Page

1189 / 1192

Location

United States

Related Subject Headings

  • Time Factors
  • Middle Aged
  • Male
  • Internal Mammary-Coronary Artery Anastomosis
  • Infusions, Intravenous
  • Humans
  • Hemostatics
  • Hemofiltration
  • Heart Valves
  • Heart Arrest, Induced